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Abstract
Background: Ulcerative colitis (UC) is a chronic inflammatory disease with a variable and unpredictable course. This disease has
noticeable consequences and by causing limitations in the life style of patients affects their quality of life.
Objectives: In this study, we evaluated the quality of life (QOL) of these patients in the remission period of this disease.
Methods: Health-related quality of life (HRQOL) in 96 patients suffering from UC in clinical remission phase were evaluated by the
use of two questionnaires of IBDQ and SF-36 which evaluate the domains of QOL and physical-psychological health, respectively.
Results were analyzed by independent sample t-test and regression analysis using of SPSS version 22.
Results: Mean total scores from SF-36 and IBDQ tests were 79.5± 17.7 and 48.8± 9.5, respectively. Based on the results of IBD-Q test,
the least score was given to the systemic symptoms (11.01± 3.17) and the most was related to the emotional function (30.06± 8.03).
In the domain of physical-psychological health, physical health (15.06 ± 25.7) compared to the psychological health (33.5 ± 7.8)
had a higher score. In addition, the mean total score from the IBD-Q test (P = 0.017), intestinal symptoms (P = 0.015) and emotional
function (P = 0.007) were statistically more significant in males compared to the females.
Conclusions: In patients suffering from UC in the remission phase males had a better HRQOL compared to females. Also remission
period and absence of EIM have a positive effect on the QOL of these patients.
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1. Background
Ulcerative colitis (UC) is a chronic inflammatory bowel
disease with a variable and unpredictable course of im-
munological response and morphologic alterations in
colon (1, 2). This inflammation is confined to its mucosa
and depending on its severity can manifest from edema to
ulcer and bleeding in a part or in whole colon (3). Major
symptoms of this disease are as diarrhea, abdominal pain,
lower gastrointestinal bleeding (LGIB), weight loss and fa-
tigue which may result in noticeable social and psycholog-
ical consequences limiting the life style of these patients
thereby affecting their quality of life (QOL) (4). According
to the epidemiological studies, the prevalence of this dis-
ease is increasing in the recent years and it usually affects
the younger individuals with its peak from 20 to 40 years of
age. Its prevalence ranges from 4.9 - 505, 4.9 - 168.3, and 37.5
- 248.6 per 100,000 persons for UC in Europe, Asia and Mid-
dle East, and North America, respectively. The incidence
and prevalence rates of UC have increased in the last 4 - 5
decades (5).
Etiological factors of this disease are not yet well under-
stood, but in appropriate genetic background immuno-
logic and environmental factors play important roles in
its pathogenesis (6). Effective therapeutic modalities for
patients suffering from UC is not well clarified and each
patient’s therapeutic response is variable (7). Previous
studies have shown that the health-related quality of life
(HRQOL) in patients suffering from UC is lower compared
to the healthy individuals (8, 9). Many studies have
shown that the medical treatment (corticosteroids and
immunosuppressive-drugs) (8), extra-intestinal manifes-
tations (10) and employment status (11) are among the fac-
tors which reduce the HRQOL of patients suffering from
UC (12, 13). In addition, there are contradictory data in
regard to the effect of therapeutic regimens of UC on
HRQOL. Some reports denote the negative effect of thera-
pies based on immunosuppressive-drugs on HRQOL (1, 14),
while other studies have failed to prove this relation (15).
Nowadays, the first priority is to understand how UC
and its related domains can affect the well-being and to
what extent. Most of studies have evaluated the HRQOL in
patients with active UC. Therefore, evaluating the QOL of
patients suffering from UC is not only to improve the symp-
toms in different stages of disease, but it is also important
in planning and guiding the medical or surgical treatment
in order to improve the QOL.
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2. Objectives
In this study, we are attempting to evaluate the QOL of
patients in the clinical remission by assessing their data in
respect to the severity of disease, its durations and received
treatments.
3. Methods
This descriptive analytic study is performed with the
aim to determine the effective factors on QOL of patients
suffering from UC in clinical remission phase based on the
demographic characteristics. 96 patients suffering from
UC whose diagnosis was confirmed by adult gastroenterol-
ogists based on the clinical, colonoscopy, pathologic and
imaging (if needed) were participated in this study from
April 2007 to March 2015 at Rahimian Charity hospital in
Qazvin (Iran). Patients were monitored by being in clinical
remission for the past 6 months. Exclusion criteria were
such as suffering from another disease affecting their QOL,
drug abuse and psychiatric disease. A filled informed con-
sent form were obtained from the patients by fully advis-
ing them about the details and the goals of the study. Pa-
tients were asked to fill in two questionnaires.
3.1. Evaluation of Effect of Disease on HRQOL
In order to evaluate the effect of disease on HRQOL,
two standard questionnaires of IBDQ and SF-36 were
used which evaluate the domains of QOL and physical-
psychological health, respectively. IBDQ questionnaire
which evaluates the patients QOL is composed of 32 ques-
tions which are categorized in four groups; intestinal
symptoms (10 questions), systemic symptoms (5 ques-
tions); emotional (12 questions) and social function (5
questions). For each question, seven answers were consid-
ered as of score 1 denoting for the worst and score 7 for the
best status. Total score for each individual is varied from
32 to 224 and the higher the score was the better was his or
her status. Validity and reliability of IBDQ questionnaire in
Persian language was evaluated by Maleki et al. in 2015 in
Iran, showing a good validity and reliability to evaluate the
QOL patients suffering from UC (16).
SF-36 questionnaire is mainly evaluating the domain
of physical-psychological health by vitality, physical func-
tioning, body pain, general health perceptions, physical,
emotional and social role functioning and mental health.
In addition, SF-36 also summarizes two general measures,
physical component summary scores (PCS) and mental
component summary scores (MCS) which evaluates the
psycho-social health. Score range in each of these domains
varies from 0 to 100 and the higher score denotes a bet-
ter QOL. Validity and reliability of this questionnaire in Ira-
nian population has been confirmed (17). Questionnaires
are completed bya trained personnel and also the techni-
cal section is filled in by a gastroenterologist.
After data collection, descriptive and analytical statisti-
cal tests including two independent samples t-test and re-
gression analysis were performed using SPSS software of 22
versions. Descriptive statistics data are reported as per per-
centage, mean and standard deviation. Normality of data
was checked by the Kolmogorov–Smirnov test (K-S test) and
also using Q-Q normal plot for exact evaluation, confirm-
ing normality test. Statistical significant was considered as
P < 0.05.
4. Results
In this study, data from 96 patients suffering from UC
were investigated. 82 cases (85.2%) were in the phase of clin-
ical remission (i.e. based on the absence of diarrhea and
visible blood in stool, without any systemic sign or symp-
tom and bowel movement of 1-3 times a day). 44 (45.8%) pa-
tients were male and 52 (54.2%) were female. Their mean
age was 37.9 ± 12.44 ranging from 14 to 70 years and the
mean of 32.9 ± 12.8 months was elapsed from their di-
agnosis. Most patients with the prevalence of 92 cases
(95.8%) were city dwellers. Most patients, 80 cases (87.9%)
had never smoked cigarettes. The largest complains of
patients from extra-intestinal manifestations (EIM) were
rheumatologic with the prevalence of 30 (35.8%) cases and
44 (52.4%) patients were devoid of any EIM. The largest
bowel movements were from 1 to 3 times (85.2%) a day and
with the prevalence of 20 (20.5%) nocturnal bowel move-
ments. Other demographic data of patients are summa-
rized in Table 1.
Total and individual scores relating to the IBDQ and
SF-36 are shown in Table 2. Mean of total score from the
IBDQ test was 79.5± 17.7. In the domain of QOL results, of
IBD-Q test showed that the least score was given to the sys-
temic symptoms (11.01 ± 3.17) while the most was related
to the emotional function (30.06± 8.03). Mean total score
from SF-36 score was 48.8± 9.5. In the domain of physical-
psychological health, physical health (15.06± 25.7) as com-
pared to the psychological health (33.5± 7.83) had a higher
score.
In comparing the mean score of domains of QOL and
physical-psychological health of patients suffering from
UC by gender, results from the two independent samples
t-test showed that mean total score obtained from the IBD-
Q test (P = 0.017), also mean scores of intestinal symptoms
(P = 0.015) and emotional function (P = 0.007) were statis-
tically and highly significant in males compared to the fe-
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Table 1. Description of Demographic Attributes of Patients Suffering from UC (n =
96)
Variable No. (%)
Marital status
Married 79 (83.2)
Single 16 (16.8)
Occupation
Government job 13 (13.7)
Private job 14 (14.7)
House wife 38 (40)
Retired 15 (15.8)
Self-employed/Laborer 15 (15.8)
Educational level
Under diploma 32 (35.6)
Diploma and upper 32 (35.6)
University and upper 26 (28.9)
Relapsewith drug usage
Yes 37 (48.1)
No 40 (51.9)
Relapsewithout drug
Yes 16 (51.6)
No 15 (48.4)
Extra-intestinalmanifestations (EIM)
Yes 52 (54.2)
No 44 (45.8)
Disease extent
Distal colitis 48 (50)
Left side colitis 30 (31.2)
Pan colitis 18 (18.8)
Type of treatment
ASA 69 (77.5)
Corton 4 (4.5)
AZA 13 (14.6)
Renitec 3 (3.4)
males. Comparing the mean of total score obtained from
the SF-36 test and its domains did not show a significant dif-
ference in the domain of physical-psychological health be-
tween female and male (P > 0.05). These results are shown
in Table 3 and Figure 1.
In evaluating the effect of variables on QOL and
physical- psychological health of patients suffering from
UC, results of regression analysis showed that the factors of
gender (male) (P = 0.025) and the remission duration (P =
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Figure 1. Plot of Mean± 2SD of Each Domain Vs. Gender
0.042) and absence of EIM (extra-intestinal manifestation)
(P = 0.04) were effective on QOL and in the SF-36 scale, the
gender (male) (P = 0.019) was the only significant variable.
These results are shown in Table 4.
In order to better evaluate the results of IBDQ test, in
Table 5 scores obtained from this test was compared with
the other studies (3, 18, 19). Results from this population
study show that the HRQL in general is noticeably lower
compared to that of the other studies.
5. Discussion
Data from this study show that the HRQL is better in
males compared to the females suffering from UC, in clini-
cal remission phase. In addition, intestinal symptoms and
emotional functions are better in males compared to the
females. Evaluation of relation between gender and QOL
by kamrowska et al., (2010) showed that the females had a
lower HRQOL compared to males, which is consistent with
our data. In contradistinction, another study showed sim-
ilar relation in males (20). In contrast, there were other
studies in which no relation was found between the gen-
der and QOL (19, 21). Our results show that males had a
better emotional function than females; Therefore it seems
that females had a more emotional affection from this dis-
ease because it not only affects their health but also affects
their attractiveness, social and sexual relation. Further-
more, studies have shown that the relapse of the disease
often affects females more seriously compared to males (1).
Regarding the scores of IBDQ questionnaire of QOL, in
our results the least score was in domain of systemic symp-
toms and the most was in the domain of emotional func-
tion, evaluation of other studies showed a similar pattern
(3, 18, 19). But total sum of score obtained from our pop-
ulation study show a lower QOL compared to other stud-
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Table 2. Description Statistic of the Domains of QOL and Physical and Psychological Health of Patients
Scale Min Max Mean SD
Total IBDQ score 40 100 79.5 17.7
Bowel symptoms 14 36 25.03 5.6
Systemic symptoms 2 16 11.01 3.17
Emotional functioning 13 44 30.06 8.03
Social functioning 4 16 12.5 3.3
Total SF-36 score 28 65 48.8 9.5
Psychological health 18 47 33.5 7.8
Physical health 7 19 15.06 25.7
Table 3. Comparison Between the Mean of Domains in Different Gender Using T-Test
Scale Female Male P Valuea
Mean SD Mean SD
Total IBDQ score 74.4 18.8 85 14.8 0.017
Bowel symptoms 23.5 5.9 27.6 4.9 0.015
Systemic symptoms 10.5 3.5 11.6 2.8 0.095
Emotional functioning 27.7 7.9 32.5 7.4 0.007
Social functioning 12.63 3.5 12.7 2.8 0.578
Total SF-36 score 47.6 10.03 50.5 8.6 0.189
Psychological health 32.3 8.1 35.02 7.3 0.124
Physical health 14.8 2.8 15.3 2.6 .0392
aP value is significant at the 0.05 level.
ies. In a study by Casellas et al., (2001) showed that the QOL
of patients suffering from IBD during the relapse of dis-
ease has been completely deranged. The most important
symptoms and issues which a physician should exert spe-
cial efforts to treat are the gastrointestinal and psycholog-
ical symptoms during the relapse period but when the pa-
tient is in remission phase special attention has to be given
to his or her systemic symptoms. Based upon the results
of above- mentioned study, the social disorders of suffer-
ers from active disease is less affected than the other issues
of patients’ life. Emotional function is more deranged as
compared to other issues of life which is still obvious even
after being in remission (22). Our data show that the fac-
tors such as gender, duration of remission and absence of
EIM (extra-intestinal manifestation) were effective on QOL
and in the SF-36 scale.
Other demographic factors evaluated in this study
such as marital status, occupation, education and type of
treatment had no effect on the QOL patients suffering from
UC in the clinical remission. In a study on QOL of pa-
tients suffering from UC, no significant relation was found
among variable of gender, age and cigarette smoking to
the lessened score of IBDQ in any of the investigated do-
mains (23). Different studies have shown that the level
of disease activity noticeably affects the QOL (24, 25). Pa-
tients with more severe symptoms have obtained lower
score as compared to those with less severity of symptoms
and hence they had lower QOL. Therefore, our data are con-
sistent with the results obtained from previous studies re-
garding the significant effect of remission duration of dis-
ease and absence of EIM on QOL in patients.
Also our data show that patient’s occupation had no
effect on their QOL in remission phase. Results of studies
by Hoivik et al., (2012) (1) showed that occupational condi-
tions as compared with disease relapse more negatively af-
fects the QOL of males.
Here, we conclude that perhaps the social conse-
quences of disease affect the QOL of patients more than
disease itself. Different studies have shown the relation be-
tween higher educational level and better QOL in patients
suffering from UC in active phase (26).This perhaps could
be related to, having more knowledge and higher capabil-
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Table 4. Regression Analysis Data of Effective Factors on QOL and Psychological and Physical Health of Patients
Variable SF-36 P Value IBDQ P Value
Beta SE Beta SE
Gender (male) 10.12 11.4 0.019* 18.9 7.3 0.025a
Diseases inactive duration 1.31 0.72 0.214 0.98 0.065 0.042a
Extra-intestinalmanifestations (No) 8.3 3.1 0.211 16.9 5.6 0.04a
aIs significant at the 0.05 level.
Table 5. Comparison of IBDQ Test’s Score of Our Study with Others
Scale de Boer et al. (1995) Han et al. (2005) Cohen et al. (2010) Present Results
Total IBDQ score 119.1 173.7 166.36 79.5
Bowel symptoms 37.3 54.9 55 25.03
Systemic symptoms 17 25.3 23.72 11.01
Emotional functioning 44.9 64.1 59.6 30.06
Social functioning 20 29.4 28.52 12.5
ity to obtain better information and consequently better
practice. Our data did not show a relation between the
level of education and QOL of patients suffering from UC in
remission phase. It seems that having a more knowledge to
better manage the disease has a direct and better effect on
the QOL of patients.
Different studies have reported contradictory results
on the type of medicines used in the treatment and QOL,
some studies have reported no relation between the type
of treatment received and QOL while the results from an-
other studies have shown that systemic corticosteroids,
immunosuppressive-drugs and anti TNF-α exert negative
effects on the QOL of this patients (14, 15, 23, 27). Our data
did not show a significant difference between the type of
treatment received and QOL in the patients. At the end, it
can finally be concluded that in patients suffering from UC
in the clinical remission phase males had a better HRQOL
compared to females and absence of EIM has a positive ef-
fect on the QOL of these patients.
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